Publications
Brain atrophy and white matter hyperintensities are independently associated with plasma neurofilament light chain in an Asian cohort of cognitively impaired patients with concomitant cerebral small vessel disease.
Chong JR, Hilal S, Ashton NJ, Karikari TK, Reilhac A, Vrooman H, Schöll M, Zetterberg H, Blennow K, Chen CP, Lai MKP. Alzheimers Dement (Amst). 2023 Mar 26;15(1):e12396. doi: 10.1002/dad2.12396. eCollection 2023 Jan-Mar.
Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications.
Gonzalez-Ortiz F, Kac PR, Brum WS, Zetterberg H, Blennow K, Karikari TK. Mol Neurodegener. 2023 Mar 16;18(1):18. doi: 10.1186/s13024-023-00605-8.
Clinical performance and head-to-head comparison of CSF p-tau235 with p-tau181, p-tau217 and p-tau231 in two memory clinic cohorts.
Lantero-Rodriguez J, Vrillon A, Fernández-Lebrero A, Ortiz-Romero P, Snellman A, Montoliu-Gaya L, Brum WS, Cognat E, Dumurgier J, Puig-Pijoan A, Navalpotro-Gómez I, García-Escobar G, Karikari TK, Vanmechelen E, Ashton NJ, Zetterberg H, Suárez-Calvet M, Paquet C,...
Blood-brain barrier opening of the default mode network in Alzheimer’s disease with magnetic resonance-guided focused ultrasound.
Meng Y, Goubran M, Rabin JS, McSweeney M, Ottoy J, Pople CB, Huang Y, Storace A, Ozzoude M, Bethune A, Lam B, Swardfager W, Heyn C, Abrahao A, Davidson B, Hamani C, Aubert I, Zetterberg H, Ashton NJ, Karikari TK, Blennow K, Black SE, Hynynen K, Lipsman N. Brain. 2023...
Plasma biomarkers for neurodegenerative disorders: ready for prime time?
Balogun WG, Zetterberg H, Blennow K, Karikari TK. Curr Opin Psychiatry. 2023 Mar 1;36(2):112-118. doi: 10.1097/YCO.0000000000000851. Epub 2023 Jan 16.
Brain-derived tau: a novel blood-based biomarker for Alzheimer’s disease-type neurodegeneration.
Gonzalez-Ortiz F, Turton M, Kac PR, Smirnov D, Premi E, Ghidoni R, Benussi L, Cantoni V, Saraceno C, Rivolta J, Ashton NJ, Borroni B, Galasko D, Harrison P, Zetterberg H, Blennow K, Karikari TK. Brain. 2023 Mar 1;146(3):1152-1165. doi: 10.1093/brain/awac407.
Genetic risk for attention-deficit/hyperactivity disorder predicts cognitive decline and development of Alzheimer’s disease pathophysiology in cognitively unimpaired older adults.
Leffa DT, Ferrari-Souza JP, Bellaver B, Tissot C, Ferreira PCL, Brum WS, Caye A, Lord J, Proitsi P, Martins-Silva T, Tovo-Rodrigues L, Tudorascu DL, Villemagne VL, Cohen AD, Lopez OL, Klunk WE, Karikari TK, Rosa-Neto P, Zimmer ER, Molina BSG, Rohde LA, Pascoal TA;...
Astrocyte reactivity influences the association of amyloid-β and tau biomarkers in preclinical Alzheimer’s disease.
Pascoal T, Bellaver B, Povala G, Ferreira P, Ferrari-Souza JP, Leffa D, Lussier F, Benedet A, Ashton N, Triana-Baltzerz G, Kolbzh H, Tissot C, Therriault J, Servaes S, Stevenson J, Rahmouni N, Lopez O, Tudorascu D, Villemagne V, Ikonomovic M, Gauthier S, Zimmer E,...
Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography.
Therriault J, Vermeiren M, Servaes S, Tissot C, Ashton NJ, Benedet AL, Karikari TK, Lantero-Rodriguez J, Brum WS, Lussier FZ, Bezgin G, Stevenson J, Rahmouni N, Kunach P, Wang YT, Fernandez-Arias J, Socualaya KQ, Macedo AC, Ferrari-Souza JP, Ferreira PCL, Bellaver B,...
A Validated Method to Prepare Stable Tau Oligomers.
Hill E, Moffat KG, Wall MJ, Zetterberg H, Blennow K, Karikari TK. Methods Mol Biol. 2023;2551:203-224. doi: 10.1007/978-1-0716-2597-2_14.
Functional Applications of Stable Tau Oligomers in Cell Biology and Electrophysiology Studies.
Hill E, Moffat KG, Wall MJ, Zetterberg H, Blennow K, Karikari TK. Methods Mol Biol. 2023;2551:147-161. doi: 10.1007/978-1-0716-2597-2_11.
CSF tau368/total-tau ratio reflects cognitive performance and neocortical tau better compared to p-tau181 and p-tau217 in cognitively impaired individuals.
Simrén J, Brum WS, Ashton NJ, Benedet AL, Karikari TK, Kvartsberg H, Sjons E, Lussier FZ, Chamoun M, Stevenson J, Hopewell R, Pallen V, Ye K, Pascoal TA, Zetterberg H, Rosa-Neto P, Blennow K. Alzheimers Res Ther. 2022 Dec 22;14(1):192. doi:...
Antibody-free measurement of cerebrospinal fluid tau phosphorylation across the Alzheimer’s disease continuum.
Gobom J, Benedet AL, Mattsson-Carlgren N, Montoliu-Gaya L, Schultz N, Ashton NJ, Janelidze S, Servaes S, Sauer M, Pascoal TA, Karikari TK, Lantero-Rodriguez J, Brinkmalm G, Zetterberg H, Hansson O, Rosa-Neto P, Blennow K. Mol Neurodegener. 2022 Dec 12;17(1):81. doi:...
CSF biomarkers and plasma p-tau181 as predictors of longitudinal tau accumulation: Implications for clinical trial design.
Moscoso A, Karikari TK, Grothe MJ, Ashton NJ, Lantero-Rodriguez J, Snellman A, Zetterberg H, Blennow K, Schöll M. Alzheimers Dement. 2022 Dec;18(12):2614-2626. doi: 10.1002/alz.12570. Epub 2022 Feb 28.
Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer’s trial selection and disease monitoring.
Ashton NJ, Janelidze S, Mattsson-Carlgren N, Binette AP, Strandberg O, Brum WS, Karikari TK, González-Ortiz F, Di Molfetta G, Meda FJ, Jonaitis EM, Koscik RL, Cody K, Betthauser TJ, Li Y, Vanmechelen E, Palmqvist S, Stomrud E, Bateman RJ, Zetterberg H, Johnson SC,...
Astrocyte biomarker signatures of amyloid-β and tau pathologies in Alzheimer’s disease.
Ferrari-Souza JP, Ferreira PCL, Bellaver B, Tissot C, Wang YT, Leffa DT, Brum WS, Benedet AL, Ashton NJ, De Bastiani MA, Rocha A, Therriault J, Lussier FZ, Chamoun M, Servaes S, Bezgin G, Kang MS, Stevenson J, Rahmouni N, Pallen V, Poltronetti NM, Klunk WE, Tudorascu...
Ante-mortem plasma phosphorylated tau (181) predicts Alzheimer’s disease neuropathology and regional tau at autopsy.
Morrison MS, Aparicio HJ, Blennow K, Zetterberg H, Ashton NJ, Karikari TK, Tripodis Y, Martin B, Palmisano JN, Sugarman MA, Frank B, Steinberg EG, Turk KW, Budson AE, Au R, Goldstein LE, Jun GR, Kowall NW, Killiany R, Qiu WQ, Stern RA, Mez J, McKee AC, Stein TD,...
Evaluation of in vivo staging of amyloid deposition in cognitively unimpaired elderly aged 78-94.
Michalowska MM, Herholz K, Hinz R, Amadi C, McInnes L, Anton-Rodriguez JM, Karikari TK, Blennow K, Zetterberg H, Ashton NJ, Pendleton N, Carter SF. Mol Psychiatry. 2022 Oct;27(10):4335-4342. doi: 10.1038/s41380-022-01685-6. Epub 2022 Jul 20.
Investigating the use of plasma pTau181 in retired contact sports athletes.
Vasilevskaya A, Taghdiri F, Multani N, Ozzoude M, Tarazi A, Khodadadi M, Wennberg R, Rusjan P, Houle S, Green R, Colella B, Blennow K, Zetterberg H, Karikari T, Mikulis D, Hazrati LN, Kovacs GG, Davis KD, Tator C, Tartaglia MC. J Neurol. 2022 Oct;269(10):5582-5595....
Publisher Correction: Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease.
Milà-Alomà M, Ashton NJ, Shekari M, Salvadó G, Ortiz-Romero P, Montoliu-Gaya L, Benedet AL, Karikari TK, Lantero-Rodriguez J, Vanmechelen E, Day TA, González-Escalante A, Sánchez-Benavides G, Minguillon C, Fauria K, Molinuevo JL, Dage JL, Zetterberg H, Gispert JD,...
Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease.
Milà-Alomà M, Ashton NJ, Shekari M, Salvadó G, Ortiz-Romero P, Montoliu-Gaya L, Benedet AL, Karikari TK, Lantero-Rodriguez J, Vanmechelen E, Day TA, González-Escalante A, Sánchez-Benavides G, Minguillon C, Fauria K, Molinuevo JL, Dage JL, Zetterberg H, Gispert JD,...
N-terminal and mid-region tau fragments as fluid biomarkers in neurological diseases.
Snellman A, Lantero-Rodriguez J, Emeršič A, Vrillon A, Karikari TK, Ashton NJ, Gregorič Kramberger M, Čučnik S, Paquet C, Rot U, Zetterberg H, Blennow K. Brain. 2022 Aug 27;145(8):2834-2848. doi: 10.1093/brain/awab481.
Plasma p-tau181 shows stronger network association to Alzheimer’s disease dementia than neurofilament light and total tau.
Frank B, Ally M, Brekke B, Zetterberg H, Blennow K, Sugarman MA, Ashton NJ, Karikari TK, Tripodis Y, Martin B, Palmisano JN, Steinberg EG, Simkina I, Turk KW, Budson AE, O'Connor MK, Au R, Goldstein LE, Jun GR, Kowall NW, Stein TD, McKee AC, Killiany R, Qiu WQ, Stern...
Effect of Race on Prediction of Brain Amyloidosis by Plasma Aβ42/Aβ40, Phosphorylated Tau, and Neurofilament Light.
Schindler SE, Karikari TK, Ashton NJ, Henson RL, Yarasheski KE, West T, Meyer MR, Kirmess KM, Li Y, Saef B, Moulder KL, Bradford D, Fagan AM, Gordon BA, Benzinger TLS, Balls-Berry J, Bateman RJ, Xiong C, Zetterberg H, Blennow K, Morris JC. Neurology. 2022 Jul...
Comorbidities confound Alzheimer’s blood tests.
Schindler SE, Karikari TK. Nat Med. 2022 Jul;28(7):1349-1351. doi: 10.1038/s41591-022-01875-3.
Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility.
Karikari TK, Ashton NJ, Brinkmalm G, Brum WS, Benedet AL, Montoliu-Gaya L, Lantero-Rodriguez J, Pascoal TA, Suárez-Calvet M, Rosa-Neto P, Blennow K, Zetterberg H. Nat Rev Neurol. 2022 Jul;18(7):400-418. doi: 10.1038/s41582-022-00665-2. Epub 2022 May 18.
Editorial: Blood Biomarkers of Neurodegenerative Diseases.
Karikari TK, Ashton NJ, Zetterberg H, Blennow K. Front Mol Neurosci. 2022 Jun 30;15:966139. doi: 10.3389/fnmol.2022.966139. eCollection 2022.